VolitionRx

A portion of the funding, which is from the government of the Wallonia region of Belgium, is repayable over 12 years.

VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.

The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.

The company also plans to get started this year on preparations for bringing future tests through the US Food and Drug Administration.

The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.

The tests are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications.

The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.

The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.

The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.

The firm closed its offering of 2,475,000 shares of stock at a price of $3.75 per share. It plans to use the proceeds to fund colorectal cancer clinical trials. 

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.